SAN

74.48

-6.77%↓

SRT3

215.15

-1.67%↓

ORNBV.FI

68.5

+3.4%↑

SAN

74.48

-6.77%↓

SRT3

215.15

-1.67%↓

ORNBV.FI

68.5

+3.4%↑

SAN

74.48

-6.77%↓

SRT3

215.15

-1.67%↓

ORNBV.FI

68.5

+3.4%↑

SAN

74.48

-6.77%↓

SRT3

215.15

-1.67%↓

ORNBV.FI

68.5

+3.4%↑

SAN

74.48

-6.77%↓

SRT3

215.15

-1.67%↓

ORNBV.FI

68.5

+3.4%↑

Search

Laboratorios Farmaceuticos Rovi SA

Deschisă

SectorSănătate

79.55 1.66

Rezumat

Modificarea prețului

24h

Curent

Minim

79.55

Maxim

79.8

Indicatori cheie

By Trading Economics

Venit

-33M

43M

Vânzări

7.9M

218M

P/E

Medie Sector

33.602

67.147

EPS

0.834

Marjă de profit

19.539

Angajați

1,950

EBITDA

-21M

63M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+9.26% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

79M

4.1B

Deschiderea anterioară

77.89

Închiderea anterioară

79.55

Sentimentul știrilor

By Acuity

50%

50%

176 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mai 2026, 22:17 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Câștiguri

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Achiziții, Fuziuni, Preluări

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Câștiguri

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Câștiguri

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Câștiguri

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Câștiguri

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Câștiguri

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

9.26% sus

Prognoză pe 12 luni

Medie 86.75 EUR  9.26%

Maxim 90 EUR

Minim 83.5 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

176 / 347 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat